Johnson & Johnson to Buy Ollin for $3.4 Billion

The Texas biotech's backers could receive $2.2 billion upfront, with another $1.2 billion in potential milestone payments under discussed terms.

Updated on Nov. 16, 2026 in Biotech

Photograph of a low pale concrete research building with blue glass beside a steel greenhouse on a flat green campus lawn under overcast sky.
Johnson & Johnson may announce a deal to acquire Texas biotech Ollin Biosciences for up to $3.4 billion as soon as Monday, sources said. AI Illustration. Upload story photo >

Johnson & Johnson may announce a deal to acquire Ollin Biosciences for up to $3.4 billion, as soon as Monday, according to the extraction's reporting. Under discussed terms, the drugmaker would pay Ollin's backers $2.2 billion in cash upfront plus $1.2 billion in potential milestone payments.

Why it matters

The potential deal would extend Johnson & Johnson's pattern of biotech acquisitions, following its purchase of Firefly Bio for $1 billion in cash this year. Ollin's experimental eye disease drug is in late-stage development, making the transaction a bet on its progress through clinical studies.

Ollin is advancing OLN324, an experimental drug being studied for diabetic macular edema and wet age-related macular degeneration, after raising $330 million in June. The pipeline's late-stage status and the milestone structure tie part of the payment to future development results.

The players

Johnson & Johnson

A major American multinational pharmaceutical and medical device company headquartered in New Brunswick, New Jersey, known for its large-scale biotech acquisitions.

Ollin Biosciences

A Texas-based biotech company developing OLN324, an experimental treatment for diabetic macular edema and wet age-related macular degeneration.

The details

Ollin Biosciences, a Texas-based biotech company, is the target under discussion, with the deal reportedly combining upfront cash with milestone-based payments. Ollin raised $330 million in June to fund late-stage studies of OLN324, its experimental treatment for eye diseases.

Timeline

  1. June: Ollin raised $330 million to advance late-stage studies of OLN324.

  2. 2025: Johnson & Johnson acquired Intra-Cellular Therapies for $14.6 billion.

  3. This year: Johnson & Johnson acquired Firefly Bio for $1 billion in cash.

  4. As soon as Monday: Johnson & Johnson could announce the Ollin deal.

The Tech Race

The potential Ollin acquisition extends Johnson & Johnson's pattern of buying drug developers to replenish its pipeline, following its $14.6 billion purchase of Intra-Cellular Therapies in 2025. It is smaller in scale than that deal, reflecting a strategy of mixing large and mid-sized biotech acquisitions.

If the deal closes, OLN324's late-stage development could determine whether a new treatment for diabetic macular edema and wet age-related macular degeneration reaches patients. Because the milestone payments depend on future progress, the timing of any eventual treatment availability remains uncertain.

The takeaway

Large drugmakers are increasingly combining upfront payments with milestone-based structures to manage the risk of acquiring early and late-stage therapies. The Ollin deal, if announced, would illustrate how that balance is struck for an experimental eye disease drug.

What happens next

Johnson & Johnson could announce the Ollin Biosciences deal as soon as Monday, though the extraction does not confirm a signed agreement.

Further reading

For more on how drugmakers are pursuing new treatments, explore Biotech coverage.